The optimal time for hematopoietic stem cell translantation for Hodgkin's lymphoma. International guidelines and real practic in Russia and former USSSR countries (Part II)

The influence of previous antitumor therapy the efficacy and tolerability of high-dose chemotherapy with autologous hematopoietic progenitor cells transplantation (HCST) in 369 patients with Hodgkin, s lymphoma in the clinics of Russia and CIS countries was analyzed. Longterm treatment results of patients who have received 1 or 2 therapy lines before deciding about HCST were comparable (5‑year overall survival (OS) – 67 ± 3.8 % and 71 ± 5.0 %; freedom from treatment failure survival (FFTF) – 52.6 ± 3.9 % and 61 ± 5.0 %, respectively). The worst results (p < 0.05) are in patients who have received > 2 lines of therapy prior HSCT (5‑year OS – 46 ± 9.7 %, FFTF – 38.4 ± 9.0 %). The negative impact of previous treatment on the efficiency of hematopoietic material collection and hematopoiesis reconstitution as well observed in patients who received > 2 lines of therapy. Therefore, if the delay of HSCT in patients who achieved remission on secondline therapy was caused by organizational problems, for optimum results is necessary to conduct HSCT not later than second relapse while maintaining tumor chemosensitivity (third disease remission). However, when remission is not achieved after second-line therapy, is necessary to change the treatment regimen and performing HSCT only at confirmation of tumor chemosensitivity, because regardless of prior therapy line number, this approach leads to better results than earlier performing HSCT without remission.

1. Жуков Н. В., Усс А. Л., Миланович Н. Ф. и др. Оптимальное время для проведения аутологичной трансплантации клеток предшественников гемопоэза при неблагоприятном течении лимфомы Ходжкина. Зарубежные рекомендации и отечественная практика. Онкогематол 2014;2:37–44.

2. Hoppe R. T., Advani R. H., Ai W. Z. et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10(5):589–97.

3. Eichenauer D. A., Engert A., Dreyling M.; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 Suppl 6: vi55–8.

4. Collins G. P., Parker A. N., Pocock C. et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol 2014;164(1): 39–52.

5. Linch D. C., Winfield D., Goldstone A. H. et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051–4.

6. Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: а randomised trial. Lancet 2002;359(9323):2065–71.

7. Schmitz N., Haverkamp H., Josting A. et al. Long term follow up in relapsed Hodgkin’s disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Proc ASCO 2005;23:562S.

8. Sureda A., Arranz R., Iriondo A. et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas / Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001;19(5):1395–404.

9. http://www.nccn.org /professionals / physician_gls / PDF /hodgkins.pdf.

10. Moskowitz C. H., Matasar M. J., Zelenetz A. D. et al. Normalization of pre-ASCT, FDG-PET imaging with econd-line, non – cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012;119(7):1665–70.

11. Constans M., Sureda A., Terol M. J. et al. Autologous stem cell transplantation for primary refractory Hodgkin’s disease: results and clinical variables affecting outcome. Ann Oncol 2003;14(5):745–51.

12. Chopra R., McMillan A.K., Linch D. C. et al. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single center 8‑year study of 155 patients. Blood 1993;81(5):1137–45.

13. Moskowitz C. H., Kewalramani T., Nimer S. D. et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsyproven primary refractory Hodgkin's disease. Br J Haematol 2004;124(5):645–52.

14. Ferme C., Mounier N., Divine M. et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy: results of the Groupe d’Etudes des Lymphomes de l’Adulte H89 Trial. J Clin Oncol 2002; 20(2):467–75.

15. Josting A., Rueffer U., Franklin J. et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000;96(4):1280–6.